NATIONAL JEWISH HEALTH
Programs
National Jewish Health Clinical Services
National Jewish Health is a nationally recognized, academic medical center with specialized expertise in the evaluation and management of respiratory, cardiac, allergic and immunologic diseases. National Jewish Health serves as a referral center for patients across the United States, particularly for those patients with diseases that are exceptionally difficult to diagnose and/or treat. National Jewish Health provides care to adult and pediatric patients on both an inpatient and outpatient basis and offers a comprehensive spectrum of clinical services. Clinical services include but are not limited to: pulmonary, critical care and sleep medicine, allergy/immunology, occupational and environmental health sciences, cardiology, pulmonary, hypertension, rheumatology, gastroenterology, infectious disease and mycobacterial infections, cystic fibrosis, neurology, neuromuscular medicine and ALS, thoracic surgery, immediate care, otolaryngology and oncology. In the fiscal year ended June 30, 2023, National Jewish Health provided over 110,373 outpatient visits. Additionally, our physicians provided over 17,516 inpatient encounters, primarily critical care services, pulmonary consultative service and hospitalist services, at multiple facilities across metropolitan Denver, including the National Jewish Health main campus. Our patients come from virtually every state across the United States, with residents from our Colorado community constituting the largest single group. National Jewish Health was founded under the motto, "None may enter who can pay; None can pay who enter." While today, National Jewish Health accepts paying patients, a significant amount of charity care is provided and all appointments are offered on a first come, first served basis regardless of the ability to pay. National Jewish Health continues to adapt its clinical programs to meet the unique needs of the changing healthcare landscape, like providing telehealth services and providing multi-disciplinary clinics for patients suffering and recovering from long COVID. National Jewish Health has collaborated with local hospitals to provide a combined state of the art outpatient clinic and inpatient care setting.GeographiesNot indicatedDatesJul 1, 2022 – Jun 30, 2023Source990No causes providedNo populations provided–$237.5MBiomedical Research Initiatives
National Jewish Health receives various types of grants. In addition to the above, National Jewish Health received $51,837,060 of funding through grants which are included in Part VIII (revenues), lines 1e and 1f. National Jewish Health conducts extensive basic, translational and clinical biomedical research. In addition to translational research programs in its areas of clinical specialties, National Jewish Health conducts research in basic immunology, genetics, proteomics, cell biology, signal transduction, structural biology, cancer biology, and oxidant biology. Research activities have resulted in a number of scientific discoveries that have improved care for patients worldwide. National Jewish Health was awarded several grants to study COVID-19, as well as a federal contract to fund our COPDGene research and network. Funds for National Jewish Health's research are provided by grants from private and governmental agencies which include the National Institute of Health (NIH), the Department of Defense (DOD), National Science Foundation (NSF) and charitable contributions from private industry.GeographiesNot indicatedDatesJul 1, 2022 – Jun 30, 2023Source990No causes providedNo populations provided–$72.7MQuitline Tobacco Cessation Program
National Jewish Health is the nations' largest nonprofit provider of telephonic and technology-based commercial tobacco cessation services, delivering evidence-based, personalized telephone and online coaching programs in 21 states and for more than 90 health plans, employer groups and wellness companies. The state grant contract revenue of $14,991,071 is included in Part VIII, line 1e, while the rest of the revenue is reported in section 4c above. Since the development of our Quitline program in 2002, National Jewish Health has assisted more than 2.0 million people with their quit attempts. National Jewish Health leverages emerging research and some of the industry's most prominent thinkers to continually adapt and improve our program in order to meet the needs of our clients and participants. The Quitline program follows the best practices and industry standards published by the Centers for Diseases Control and Prevention (CDC) and North American Quitline Consortium (NAQC). National Jewish Health's protocols are research- and evidence -based. The Quitline is staffed by more than 80 professionals who are devoted to commercial tobacco use prevention and cessation. The Tobacco Cessation Coaches (Coaches) undergo rigorous training that enables them to tailor their coaching services based on participant needs using our proven-successful coaching model. For each person who reaches out to the Quitline for help, the coaches immediately engage them in their quit journey to foster success, and our results demonstrate our proven track record. Our surveys, conducted by an independent third party, show that individuals who receive our evidence-based coaching services and use cessation medications have a 37% tong-term quit rate, one of the best quit rates in the nation.GeographiesNot indicatedDatesJul 1, 2022 – Jun 30, 2023Source990No causes providedNo populations provided–$13.4M
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)